WO2006081331A3 - Quinoxaline derivatives as antitumor agents - Google Patents

Quinoxaline derivatives as antitumor agents Download PDF

Info

Publication number
WO2006081331A3
WO2006081331A3 PCT/US2006/002717 US2006002717W WO2006081331A3 WO 2006081331 A3 WO2006081331 A3 WO 2006081331A3 US 2006002717 W US2006002717 W US 2006002717W WO 2006081331 A3 WO2006081331 A3 WO 2006081331A3
Authority
WO
WIPO (PCT)
Prior art keywords
antitumor agents
quinoxaline derivatives
erastin
methods
binding partners
Prior art date
Application number
PCT/US2006/002717
Other languages
French (fr)
Other versions
WO2006081331A2 (en
Inventor
Robert R Becklin
Cindy Lou Chepanoske
John M Pelter
Longwu Qi
Paul B Robbins
Sudhir R Sahasrabudhe
Robert Selliah
Keith Simmons
Brent R Stockwell
Raj Gopal Venkat
Rechenberg Moritz Von
Eugene Zhen
Original Assignee
Prolexys Pharmaceuticals Inc
Whitehaed Inst For Biomedical
Univ Columbia
Robert R Becklin
Cindy Lou Chepanoske
John M Pelter
Longwu Qi
Paul B Robbins
Sudhir R Sahasrabudhe
Robert Selliah
Keith Simmons
Brent R Stockwell
Raj Gopal Venkat
Rechenberg Moritz Von
Eugene Zhen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolexys Pharmaceuticals Inc, Whitehaed Inst For Biomedical, Univ Columbia, Robert R Becklin, Cindy Lou Chepanoske, John M Pelter, Longwu Qi, Paul B Robbins, Sudhir R Sahasrabudhe, Robert Selliah, Keith Simmons, Brent R Stockwell, Raj Gopal Venkat, Rechenberg Moritz Von, Eugene Zhen filed Critical Prolexys Pharmaceuticals Inc
Priority to ES06733907T priority Critical patent/ES2409686T3/en
Priority to JP2007552406A priority patent/JP5139083B2/en
Priority to EP06733907A priority patent/EP1848698B1/en
Priority to NZ560320A priority patent/NZ560320A/en
Priority to BRPI0607306-9A priority patent/BRPI0607306A2/en
Priority to US11/883,092 priority patent/US8518959B2/en
Priority to AU2006208084A priority patent/AU2006208084B2/en
Priority to CA2595848A priority patent/CA2595848C/en
Publication of WO2006081331A2 publication Critical patent/WO2006081331A2/en
Publication of WO2006081331A3 publication Critical patent/WO2006081331A3/en
Priority to IL184788A priority patent/IL184788A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Abstract

The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3) . The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives, such like the compounds (1).
PCT/US2006/002717 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents WO2006081331A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES06733907T ES2409686T3 (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents
JP2007552406A JP5139083B2 (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents
EP06733907A EP1848698B1 (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents
NZ560320A NZ560320A (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents
BRPI0607306-9A BRPI0607306A2 (en) 2005-01-25 2006-01-25 quinoxaline derivatives as anti-tumor agents
US11/883,092 US8518959B2 (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents
AU2006208084A AU2006208084B2 (en) 2005-01-25 2006-01-25 Quinoxaline Derivatives as Antitumor Agents
CA2595848A CA2595848C (en) 2005-01-25 2006-01-25 Erastin and erastin binding proteins, and uses thereof
IL184788A IL184788A0 (en) 2005-01-25 2007-07-23 Quinoxaline derivatives as antitumor agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64730305P 2005-01-25 2005-01-25
US60/647,303 2005-01-25
US76222106P 2006-01-24 2006-01-24
US60/762,221 2006-01-24

Publications (2)

Publication Number Publication Date
WO2006081331A2 WO2006081331A2 (en) 2006-08-03
WO2006081331A3 true WO2006081331A3 (en) 2007-06-07

Family

ID=36694239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002717 WO2006081331A2 (en) 2005-01-25 2006-01-25 Quinoxaline derivatives as antitumor agents

Country Status (11)

Country Link
US (2) US8518959B2 (en)
EP (1) EP1848698B1 (en)
JP (1) JP5139083B2 (en)
KR (1) KR20080009048A (en)
AU (1) AU2006208084B2 (en)
BR (1) BRPI0607306A2 (en)
CA (1) CA2595848C (en)
ES (1) ES2409686T3 (en)
IL (1) IL184788A0 (en)
NZ (1) NZ560320A (en)
WO (1) WO2006081331A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (en) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituted dihydroquinazolines
DE10320780A1 (en) * 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines
DE10352499A1 (en) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituted dihydroquinazolines II
DE102004022672A1 (en) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituted azachinazolines
JP2008537726A (en) * 2005-01-25 2008-09-25 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ Elastin analogues and their use for killing cancer cells
ES2409686T3 (en) 2005-01-25 2013-06-27 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents
DE102005027517A1 (en) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Process for the preparation of dihydroquinazolines
US20120164730A1 (en) * 2005-10-11 2012-06-28 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of vdac1 and uses thereof
EP1934348B1 (en) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
AU2006330883A1 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc. 3-aryl-substituted quinazolones, and uses thereof
WO2007076085A2 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc . Fused pyrimidones and thiopyrimidones, and uses thereof
WO2008013987A2 (en) * 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
EP2269072B1 (en) 2008-03-31 2017-08-23 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
WO2011078226A1 (en) * 2009-12-22 2011-06-30 協和発酵キリン株式会社 Tricyclic compound
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014011973A2 (en) * 2012-07-13 2014-01-16 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
US11467158B2 (en) 2012-10-29 2022-10-11 Boston Medical Center Corporation BRCA1 mutations as predictive markers for topoisomerase inhibitions
CN103360327B (en) * 2012-12-13 2016-04-20 中山大学 A kind of phenonaphthazine derivative and its preparation method and application
US9580393B2 (en) 2012-12-13 2017-02-28 University Of Kansas 6-substituted quinazolinone inhibitors
PE20160685A1 (en) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc HETEROCYCLIC COMPOUNDS AND USES OF THEM
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015109009A1 (en) * 2014-01-15 2015-07-23 The Trustees Of Columbia University In The City Of New York Carbonyl erastin analogs and their use
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
CN106459011B (en) * 2014-04-01 2019-11-15 华盛顿大学 σ -2 receptors ligand drug conjugate, its preparation method and use as antitumoral compounds
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9708359B2 (en) 2015-08-06 2017-07-18 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EP3373939A4 (en) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
MA52897A (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc REDUCTION OF IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS
KR20210035805A (en) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Increased immune activity through regulation of postcellular signaling factors
WO2021050490A1 (en) * 2019-09-13 2021-03-18 The Trustees Of Columbia University In The City Of New York Methods of enhancing radiotherapy using ferroptosis inducers as radiosensitizers
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258224A (en) * 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd Bicyclic compound
WO1999021988A1 (en) * 1997-10-29 1999-05-06 Shanghai Second Medical University THE HUMAN VESICLE TRAFFICKING PROTEIN SEC22b GENE OF CBFBBA01
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
WO2002099122A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Modifiers of the p53 pathway and methods of use
US20030171316A1 (en) * 1999-07-24 2003-09-11 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040096444A1 (en) * 2002-08-16 2004-05-20 Salvatore Pizzo Identification of the endothelial receptor for the angiostatin kringle-5
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US20040248221A1 (en) * 2003-01-29 2004-12-09 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (en) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
JP2627899B2 (en) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 Production method of gene-encapsulated liposome
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE157012T1 (en) 1989-11-03 1997-09-15 Univ Vanderbilt METHOD FOR THE IN VIVO ADMINISTRATION OF FUNCTIONAL FOREIGN GENES
EP0553235A1 (en) 1990-10-01 1993-08-04 The University Of Connecticut Targeting viruses and cells for selective internalization by cells
AU1922092A (en) 1991-05-03 1992-12-21 Albert Einstein College Of Medicine Of Yeshiva University Targeted delivery of genes encoding cell surface receptors
DK0584279T3 (en) 1991-05-14 2001-06-11 Immune Response Corp Inc Targeted delivery of genes encoding immunogenic proteins
ES2149774T3 (en) 1991-06-05 2000-11-16 Univ Connecticut DIRECTED CONTRIBUTION OF GENES CODING SECRETARY PROTEINS.
EP0666923A1 (en) 1991-09-05 1995-08-16 The University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5821072A (en) 1996-02-20 1998-10-13 Sloan-Kettering Institute For Cancer Research Combinations of PKC inhibitors and therapaeutic agents for treating cancers
WO1997046671A1 (en) 1996-05-30 1997-12-11 University Of British Columbia Enhanced efficacy of liposomal antisense delivery
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
DE10013126A1 (en) 2000-03-17 2001-09-20 Bayer Ag New 6-aminoalkyl-dihydropyrimidine-5-carboxylate ester derivatives, useful as antiviral agents having strong activity against hepatitis B virus and low cytotoxicity
US7198895B2 (en) 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
EP1572923A4 (en) 2002-03-06 2007-10-31 Rigel Pharmaceuticals Inc Novel method for delivery and intracellular synthesis of sirna molecules
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
JP2005536553A (en) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
ES2343318T3 (en) 2002-11-26 2010-07-28 University Of Massachusetts ARNSIS ADMINISTRATION.
EP1439227A1 (en) 2003-01-15 2004-07-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts HPV-E6-specific siRNAs for the treatment of HPV-related tumors
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
EP1601767B1 (en) 2003-03-05 2012-04-25 Senesco Technologies, Inc. USE OF siRNA TO SUPPRESS EXPRESSION OF EIF-5A1 IN THE TREATMENT OF GLAUCOMA
ES2409686T3 (en) 2005-01-25 2013-06-27 Prolexys Pharmaceuticals, Inc. Quinoxaline derivatives as antitumor agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258224A (en) * 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd Bicyclic compound
WO1999021988A1 (en) * 1997-10-29 1999-05-06 Shanghai Second Medical University THE HUMAN VESICLE TRAFFICKING PROTEIN SEC22b GENE OF CBFBBA01
US20030171316A1 (en) * 1999-07-24 2003-09-11 Oklahoma Medical Research Foundation Use of prohibitin RNA in treatment of cancer
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
WO2002099122A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Modifiers of the p53 pathway and methods of use
US20040096444A1 (en) * 2002-08-16 2004-05-20 Salvatore Pizzo Identification of the endothelial receptor for the angiostatin kringle-5
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US20040248221A1 (en) * 2003-01-29 2004-12-09 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ABDEL-ALIM A-A M ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITIES OF 6-BROMO-2,3-DISUBSTITUTED-4-(3 H)-QUINAZOLINONES", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI, IN, vol. 33B, March 1994 (1994-03-01), pages 260 - 265, XP008066973, ISSN: 0019-5103 *
ADAM ET AL: "Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer", JBC PAPERS IN PRESS, 2002, pages 1 - 60, XP002409464 *
AGER ET AL.: "Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H)-quinazolone (Methaqualone)", J. MED. CHEM., vol. 20, no. 3, 1977, pages 379 - 386, XP002392896 *
FIGYS JURGEN ET AL: "VDAC CAN CONTROL APOPTOSIS BY CONTROLLING METABOLISM", BIOPHYSICAL JOURNAL, NEW YORK, US, US, vol. 86, no. 1, 18 February 2004 (2004-02-18), pages 463A - 464A, XP008071867, ISSN: 0006-3495 *
GUPTA C M ET AL: "A NOVEL CLASS OF HYPOGLYCAEMIC AGENTS: SYNTHESES & SAR IN 2-SUBSTITUTED 4(3H)-QUINAZOLONES, 2-SUBSTITUTED 4-HYDROXYPOLYMETHYLENEÄ5,6ÜPYRIMIDINES & 3-SUBSTITUTED 4-OXO-PYRIDOÄ1,2-ALPHAÜPYRIMIDINES", INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 9, March 1971 (1971-03-01), pages 201 - 206, XP009049284 *
IKONEN ELINA ET AL: "Prohibitin, an antiproliferative protein, is localized to mitochondria", FEBS LETTERS, vol. 358, no. 3, 1995, pages 273 - 277, XP002409463, ISSN: 0014-5793 *
KOZHEVNIKOV ET AL.: "Synthesis in the 2-aminoethyl-3-(2'-tolyl)-4-quinazolone", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 4, no. 11, 1970, pages 22 - 25, XP008066957 *
PATENT ABSTRACTS OF JAPAN vol. 1996, no. 02 29 February 1996 (1996-02-29) *
S. DOLMA ET AL.: "Identification of genotype-selective antitumor agnets using synthetic lethal chemical screening in engineered human tumor cells", CANCER CELL, vol. 3, 2003, pages 285 - 296, XP002392895 *
TANI J ET AL: "STUDIES ON BIOLOGICALLY ACTIVE HALOGENATED COMPOUNDS II. CHEMICAL MODIFICATIONS OF 6-AMINO-2-FLUOROMETHYL-3-(O-TOLY)-4(3H) QUINAZOLINONE AND THE CNS DEPRESSANT ACTIVITIES OF RELATED COMPOUNDS", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 27, no. 11, 1 November 1979 (1979-11-01), pages 2675 - 2687, XP000608776, ISSN: 0009-2363 *
VERMA M ET AL: "A NEW POTENT ANTI-INFLAMMATORY QUINAZOLONE", PHARMACOLOGICAL RESEARCH COMMUNICATIONS, ITALIAN PHARMACOLOGICAL SOCIETY, IT, vol. 13, no. 10, 1981, pages 967 - 979, XP008066964, ISSN: 0031-6989 *

Also Published As

Publication number Publication date
US8518959B2 (en) 2013-08-27
CA2595848C (en) 2014-06-17
JP5139083B2 (en) 2013-02-06
AU2006208084A1 (en) 2006-08-03
IL184788A0 (en) 2007-12-03
KR20080009048A (en) 2008-01-24
US20090214465A1 (en) 2009-08-27
AU2006208084B2 (en) 2012-07-26
US7615554B2 (en) 2009-11-10
WO2006081331A2 (en) 2006-08-03
ES2409686T3 (en) 2013-06-27
BRPI0607306A2 (en) 2009-08-25
EP1848698A2 (en) 2007-10-31
US20060211683A1 (en) 2006-09-21
JP2008531476A (en) 2008-08-14
NZ560320A (en) 2011-02-25
EP1848698B1 (en) 2013-03-13
CA2595848A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
WO2006081331A3 (en) Quinoxaline derivatives as antitumor agents
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
WO2006072615A3 (en) Triazolophthalazines as pde2-inhibitors
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2006105081A3 (en) Pharmacokinetically improved compounds
WO2007075772A3 (en) Compounds, screens, and methods of treatment
WO2006124748A3 (en) Multicyclic compounds and methods of their use
EP1824498A4 (en) Methods and compositions for treating cellular proliferative diseases
EP2239573A3 (en) Doxorubicin derivatives and conjugates for doxorubicin immunoassay
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2008045406A3 (en) Compounds, screens, and methods of treatment
WO2007022947A3 (en) 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
WO2007025303A3 (en) Non-steroidal antiandrogens
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2006020681A3 (en) Compounds and methods for the treatment of ubiquitin conjugating disorders
WO2006132739A3 (en) Novel chemical compounds
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
TW200637830A (en) Erastin and erastin binding proteins, and uses thereof
WO2007006591A3 (en) Dihalogenation of n,o-disubstituted hydroxipyridones and uses thereof
WO2003078574A3 (en) Novel metabolic targets and markers
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680009733.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 184788

Country of ref document: IL

Ref document number: 2007552406

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008931

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2595848

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 560320

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006208084

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 6406/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006208084

Country of ref document: AU

Date of ref document: 20060125

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077019501

Country of ref document: KR

Ref document number: 2006733907

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11883092

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0607306

Country of ref document: BR

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)